A Phase 1, Blinded, Placebo-Controlled, Crossover TR-701 FA Study of Blood Pressure Response Post-Tyramine Challenge

NCT01539473 Phase 1 COMPLETED

Phase 1 study to determine the effect of oral TR-701 FA on SBP response when administered with tyramine

Details

Lead sponsor	Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase	Phase 1
Status	COMPLETED
Enrolment	30
Start date	2012-02
Completion	2012-05

Conditions

• Healthy Volunteers

Interventions

• TR-701 FA with Tyramine
• Placebo-controlled withTyramine

Primary outcomes

• Systolic Blood Pressure — 14 days
  To assess tyramine dose required to cause increase of 30 mmHg in systolic blood pressure

Countries

United States